Potential Role for Valproate in the Treatment of High-Risk Brain Tumors of Childhood—Results from a Retrospective Observational Cohort Study

REFERENCES

• Gottardo N, Gajjar A. Chemotherapy for malignant brain tumors of childhood. J Child Neurol. 2008;23:1149–1159.
   Google Scholar
• Grill J, Bhangoo R. Recent development in chemotherapy of paediatric brain tumours. Curr Opin Oncol. 2007;19:612–615.
   PubMedGoogle Scholar
• Merchant TE, Li C, Xiong X, Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol. 2009;10:258–266.
   PubMed Web of Science ®Google Scholar
• Grundy RG, Wilne SA, Weston CL, Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol. 2007;8:696–705.
   PubMed Web of Science ®Google Scholar
• Wolff JEA, Driever PH, Erdlenbruch B, Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-gBM-c protocol. Cancer. 2010;116:705–712.
   PubMed Web of Science ®Google Scholar
• Duffner PK, Horowitz ME, Krischer JP, The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neuro Oncol. 1999;1:152–161.
   PubMedGoogle Scholar
• Recinos PF, Sciubba DM, Jallo GI. Brainstem tumors: where are we today? Pediatr Neurosurg. 2007;43:192–201.
   PubMedGoogle Scholar
• Broniscer A. Past, present, and future strategies in the treatment of high-grade glioma in children. Cancer Invest. 2006;24:77–81.
   PubMed Web of Science ®Google Scholar
• Jenkin RD, Boesel C, Ertel I, Brain-stem tumors in childhood: a prospective randomized trial of irradiation with and without adjuvant CCNU, VCR, and prednisone. A report of the Childrens Cancer Study Group. J Neurosurg. 1987;66:227–233.
   PubMedGoogle Scholar
• Fouladi M, Nicholson HS, Zhou T, A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study. Cancer. 2007;110:2535–2541.
   PubMed Web of Science ®Google Scholar
• Jennings MT, Sposto R, Boyett JM, Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children's Cancer Group. J Clin Oncol. 2002;20:3431–3437.
   PubMed Web of Science ®Google Scholar
• Fink KL. Chemotherapy and Anti-Epileptic Drug Interactions. In: Newton HB, ed. Handbook of Brain Tumor Chemotherapy. San Diego: Academic Press; 2006:44–57.
   Google Scholar
• Sirven JI, Wingerchuk DM, Drazkowski JF, Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc. 2004;79:1489–1494.
   PubMed Web of Science ®Google Scholar
• Henry T. The history of valproate in clinical neuroscience. Psychopharmacol Bull. 2003;37(Suppl 2):5–16.
   PubMedGoogle Scholar
• Cotariu D, Zaidman J. Valproic acid and the liver. Clin Chem. 1988;34:890–897.
   PubMed Web of Science ®Google Scholar
• van Breemen M, Wilms E, Vecht C. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 2007;6:421–430.
   Google Scholar
• Tremont-Lukats I, Ratilal B, Armstrong T, Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev. 2008;(2): CD004424.
   Google Scholar
• da Costa Moraes CA, Trompieri NM, Cavalcante Felix FH. Pediatric acute promyelocytic leukemia: all-trans-retinoic acid therapy in a Brazilian pediatric hospital. J Pediatr Hematol Oncol. 2008;30:387–390.
   Google Scholar
• Packer RJ, Lange B, Ater J, Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol. 1993;11:850–856.
   PubMed Web of Science ®Google Scholar
• Freeman CR, Kepner J, Kun LE, A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas? Int J Radiat Oncol Biol Phys. 2000;47:561–564.
   PubMed Web of Science ®Google Scholar
• Masoudi A, Elopre M, Amini E, Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res. 2008;28:2437–2442.
   PubMed Web of Science ®Google Scholar
• Goto M, Ohnishi C, Yamashina H, Effect of valproic acid on pharmacokinetics of active metabolites of cyclophosphamide in mice. J Pharmacobiodyn. 1987;10:8–14.
   Google Scholar
• Bourg V, Lebrun C, Chichmanian R, Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. Ann Oncol. 2001;12:217–219.
   PubMed Web of Science ®Google Scholar
• Wolff J, Kramm C, Kortmann R, Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. J Neurooncol. 2008;90:309–314.
   PubMed Web of Science ®Google Scholar
• Santini V, Gozzini A, Ferrari G. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab. 2007;8:383–393.
   PubMed Web of Science ®Google Scholar
• Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev. 2008;34:206–222.
   PubMed Web of Science ®Google Scholar
• Driever P, Knüpfer M, Cinatl J, Valproic acid for the treatment of pediatric malignant glioma. Klin Padiatr. 1999;211:323–328.
   PubMed Web of Science ®Google Scholar
• Göttlicher M, Minucci S, Zhu P, Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001;20:6969–6978.
   PubMed Web of Science ®Google Scholar
• Munster P, Marchion D, Bicaku E, Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res. 2009;15:2488–2496.
   Google Scholar
• Braiteh F, Soriano AO, Garcia-Manero G, Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res. 2008;14:6296–6301.
   PubMed Web of Science ®Google Scholar
• Dutta S, Cloyd J, Granneman G, Oral/intravenous maintenance dosing of valproate following intravenous loading: a simulation. Epilepsy Res. 2003;53:29–38.
   PubMedGoogle Scholar
• Burgess R, Jenkins R, Zhang Z. Epigenetic changes in gliomas. Cancer Biol Ther. 2008;7:1326–1334.
   PubMed Web of Science ®Google Scholar
• Furchert S, Lanvers-Kaminsky C, Juürgens H, Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer. 2007;120:1787–1794.
   PubMed Web of Science ®Google Scholar
• Benítez J, Arregui L, Cabrera G, Valproic acid induces polarization, neuronal-like differentiation of a subpopulation of C6 glioma cells and selectively regulates transgene expression. Neuroscience. 2008;156:911–920.
   PubMed Web of Science ®Google Scholar
• Das C, Aguilera D, Vasquez H, Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neurooncol. 2007;85:159–170.
   PubMed Web of Science ®Google Scholar
• Chinnaiyan P, Cerna D, Burgan W, Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res. 2008;14:5410–5415.
   PubMed Web of Science ®Google Scholar
• Soejima H, Zhao W, Mukai T. Epigenetic silencing of the MGMT gene in cancer. Biochem Cell Biol. 2005;83:429–437.
   PubMedGoogle Scholar
• Valentini A, Gravina P, Federici G, Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells. Cancer Biol Ther. 2007;6:185–191.
   PubMed Web of Science ®Google Scholar
• Friedman HS, Krischer JP, Burger P, Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. J Clin Oncol. 1992;10:249–256.
   PubMed Web of Science ®Google Scholar
• Mabeta P, Pepper MS. A comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agents. Angiogenesis. 2009;12:81–90.
   PubMed Web of Science ®Google Scholar
• Kieran MW, Turner CD, Rubin JB, A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol. 2005;27:573–581.
   PubMed Web of Science ®Google Scholar
• Bocci G, Francia G, Man S, Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A. 2003;100:12917–12922.
   PubMed Web of Science ®Google Scholar
• Perez J, Pardo J, Gomez C. Vincristine—an effective treatment of corticoid-resistant life-threatening infantile hemangiomas. Acta Oncol. 2002;41:197–199.
   PubMed Web of Science ®Google Scholar
• Lafay-Cousin L, Holm S, Qaddoumi I, Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. Cancer. 2005;103:2636–2642.
   PubMed Web of Science ®Google Scholar
• Bijman MN, van Nieuw Amerongen GP, Laurens N, Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton. Mol Cancer Ther. 2006;5:2348–2357.
   PubMed Web of Science ®Google Scholar
• Michaelis M, Michaelis UR, Fleming I, Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol. 2004;65:520–527.
   PubMed Web of Science ®Google Scholar